[Is anti-helicobacter therapy a rational approach in treatment of erosive and ulcerous lesions of the gastroduodenal mucosa in patients with inflamatory bowel diseases?]. / Ratsional'nost' antikhelikobakternoi terapii v lechenii érozivno-iazvennykh porazhenii gastroduodenal'noi slizistoi u bol'nykh s vospalitel'nymi zabolevaniiami kishechnika.

The study revealed changes in the oesophagogastroduodenal mucosa in 110 patients with IBD; in 60.9% of cases these changes were associated with Helicobacter pylori. 35 patients with IBD were examined to form two groups. The first group (20 patients) received rabeprazol (pariet) in a dose of 20 mg per day; the rest 15 patients were administered 120 mg of de-nol four times a day; amoxicicline and furazolidon were used as additional therapy in cases with Helicobacter pylori. The study showed that successful eradication did not always result in erosion epithelization but, on the contrary, only 40% cases of clinical and endoscopic remission were associated with Helicobacter pylori elimination. These data suggest that anti-helicobacter therapy is not a rational approach in treatment of this category of patients.

[Microcirculatory disorders in chronic erosions of the stomach]. / Mikrotsirkuliatornye narusheniia pri khronicheskikh éroziiakh zheludka.

Microcirculatory disturbances in chronic gastric erosions (CGE) were evaluated in 95 chronic gastric (CGE) patients using Doppler laser flowmetry to examine terminal blood flow of the gastric mucosa. Microcirculatory impairment in the fundal area was found in 93.7% patients with CGE, in the antral one in all the examinees. Patients with multiple and recurrent erosions and erosions associated with Helicobacter pylori had most pronounced microcirculatory disorders, especially in the antral stomach. When chronic erosions were treated with triad therapy on the basis of De-nol, the percentage of eradication exceeded 80%. The addition to therapy of the immunomodulator galavit promotes more effective and adequate restoration of blood flow in CGE patients.

[Interferon status of patients with non-specific ulcerous colitis and its correction with interferon inducers]. / Interferonovyi status bol'nykh nespetsificheskim iazvennym kolitom i ego korrektsiia induktorami interferona.

AIM: To examine validity of using interferon inductors (amixin and cycloferon) in combined treatment of patients with non-specific ulcerous colitis (NUC). MATERIAL AND METHODS: 113 NUC patients received basic antiinflammatory therapy (glucocorticoids and preparations of 5-aminosalycylic acid). Patients of groups 1 and 2 received interferon inductors (amixin and cycloferon in tables), respectively. Patients of groups 1a and 2a received placebo. All the patients were examined clinically with evaluation of interferon status and cellular immunity before and after the treatment. Colon mucosa biopsies obtained endoscopically were studied histologically. RESULTS: Alpha- and gamma-interferon production by leukocytes was substantially suppressed in all the examinees against normal levels of serum and spontaneous interferon. The interferon inductors stimulated relief of clinical symptoms and eliminated endoscopic signs of the disease. Amixin and cycloferon normalized interferon status in 36.3 and 33.3% of the treated patients, respectively. No response was registered in 9.1 and 8.4%, respectively. Improvement was seen in 54.6 and 58.3%, respectively. CONCLUSION: Cycloferon and amixin, interferon inductors, are effective in the treatment of NUC.